BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives $11.50 Consensus Target Price from Analysts

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) has received a consensus recommendation of “Hold” from the four analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $11.00.

A number of research analysts have issued reports on the stock. Rodman & Renshaw assumed coverage on shares of BioXcel Therapeutics in a research report on Tuesday, March 17th. They set a “buy” rating and a $17.00 target price on the stock. HC Wainwright cut their target price on shares of BioXcel Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. Zacks Research upgraded shares of BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, March 9th. Weiss Ratings restated a “sell (e+)” rating on shares of BioXcel Therapeutics in a research report on Wednesday, January 21st. Finally, Wall Street Zen downgraded shares of BioXcel Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday.

BioXcel Therapeutics Stock Down 3.4%

Shares of NASDAQ:BTAI opened at $1.14 on Tuesday. BioXcel Therapeutics has a 12 month low of $1.08 and a 12 month high of $8.08. The company’s 50-day moving average price is $1.53 and its two-hundred day moving average price is $1.88. The firm has a market cap of $30.87 million, a P/E ratio of -0.17 and a beta of 0.30.

BioXcel Therapeutics (NASDAQ:BTAI) last released its earnings results on Friday, March 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.58). The business had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.15 million. As a group, equities analysts predict that BioXcel Therapeutics will post -24.39 earnings per share for the current fiscal year.

Institutional Trading of BioXcel Therapeutics

Hedge funds have recently modified their holdings of the company. Diversify Wealth Management LLC acquired a new stake in shares of BioXcel Therapeutics in the 2nd quarter valued at approximately $27,000. HRT Financial LP acquired a new stake in shares of BioXcel Therapeutics in the 4th quarter valued at approximately $28,000. XTX Topco Ltd acquired a new stake in shares of BioXcel Therapeutics in the 2nd quarter valued at approximately $42,000. Goldman Sachs Group Inc. acquired a new stake in shares of BioXcel Therapeutics in the 1st quarter valued at approximately $50,000. Finally, Geode Capital Management LLC raised its position in shares of BioXcel Therapeutics by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock valued at $51,000 after acquiring an additional 6,120 shares during the period. 30.68% of the stock is currently owned by institutional investors and hedge funds.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.